Payment overview · 2025
General Payments
$612,439.45
76 reported records · 7 companies
Healthcare provider profile · identity verified
Joel L Young, MD
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Psychiatry · ROCHESTER HILLS, MI · NPI 1356325468
Verified facts
What the public records show
CMS Open Payments records show Joel L Young, MD received $612,439.45 in general payments during 2025 across 76 reported records.
Tris Pharma Inc accounted for 90.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Dyanavel Xr, Rexulti.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Rexulti by this doctor in 2024.
Tris Pharma Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Dyanavel XR as an associated drug or biological on 17868 records involving 7985 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Dyanavel Xr by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Tris Pharma Inc | Unresolved — no canonical attribution shown | $553,686.04 | 90.4% | 13 | 2025 |
| Supernus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $35,992.13 | 5.9% | 33 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $13,459.24 | 2.2% | 18 | 2025 |
| Collegium Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $5,735.17 | 0.9% | 5 | 2025 |
| Noven Therapeutics, LLC | Unresolved — no canonical attribution shown | $3,424.74 | 0.6% | 4 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $125.94 | 0.0% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $16.19 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Grant | $540,781.25 | 2 |
| Honoraria | $44,270.00 | 14 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $10,770.00 | 3 |
| Consulting Fee | $6,521.25 | 2 |
| Travel and Lodging | $4,748.55 | 21 |
| Compensation for serving as faculty or as a speaker for a medical education program | $3,300.00 | 3 |
| Food and Beverage | $2,048.40 | 31 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Dyanavel XR Normalized: dyanavel xr |
Drug | Tris Pharma Inc | $553,686.04 | 13 | 2025 |
Source payment records
|
|||||
| Qelbree Normalized: qelbree |
Drug | Supernus Pharmaceuticals, Inc. | $35,992.13 | 33 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $13,459.24 | 18 | 2025 |
Source payment records
|
|||||
| Quillichew ER Normalized: quillichew er |
Drug | Tris Pharma Inc | $12,867.44 | 9 | 2025 |
Source payment records
|
|||||
| Quillivant Normalized: quillivant |
Drug | Tris Pharma Inc | $12,867.44 | 9 | 2025 |
Source payment records
|
|||||
| Jornay PM Normalized: jornay pm |
Drug | Collegium Pharmaceutical, Inc. | $5,735.17 | 5 | 2025 |
Source payment records
|
|||||
| Xelstrym Normalized: xelstrym |
Drug | Noven Therapeutics, LLC | $3,424.74 | 4 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $125.94 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $16.19 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Dyanavel XR dyanavel xr |
2025 | Dyanavel Xr | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Tris Pharma Inc Exact reporting entity; no affiliate inference |
2025 | Dyanavel XR open payments reported associated product |
CMS Open Payments — General Payments 17868 supporting records · 7985 recipient NPIs · example record 1192249449 |
Dyanavel Xr · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Spravato | Esketamine Hcl | 103 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 50 | 13 |
| Alprazolam | Alprazolam | 47 | 26 |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 47 | 28 |
| Clonazepam | Clonazepam | 43 | 19 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 43 | 22 |
| Bupropion Xl | Bupropion Hcl | 42 | 18 |
| Vyvanse | Lisdexamfetamine Dimesylate | 38 | 14 |
| Escitalopram Oxalate | Escitalopram Oxalate | 36 | 13 |
| Duloxetine Hcl | Duloxetine Hcl | 30 | suppressed |
| Methylphenidate Er | Methylphenidate Hcl | 30 | suppressed |
| Auvelity | Dextromethorphan Hbr/Bupropion | 27 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 27 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 27 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 25 | suppressed |
| Aripiprazole | Aripiprazole | 24 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 23 | 11 |
| Lisdexamfetamine Dimesylate | Lisdexamfetamine Dimesylate | 19 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 17 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 15 | suppressed |
| Dyanavel Xr | Amphetamine | 15 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 13 | suppressed |
| Desipramine Hcl | Desipramine Hcl | 12 | suppressed |
| Gabapentin | Gabapentin | 12 | suppressed |
| Lorazepam | Lorazepam | 12 | suppressed |
| Olanzapine | Olanzapine | 11 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 11 | suppressed |
| Rexulti | Brexpiprazole | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $612,439.45 · 76 records | Tris Pharma Inc | CAPLYTA, Dyanavel XR, Jornay PM, Qelbree, Quillichew ER, Quillivant, REXULTI, VRAYLAR, Xelstrym | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Dyanavel Xr play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Lundbeck LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error